Literature DB >> 1864543

Confirmation of the efficacy of hepatic tissue iron index in differentiating genetic haemochromatosis from alcoholic liver disease complicated by alcoholic haemosiderosis.

R W Sallie1, W D Reed, K B Shilkin.   

Abstract

The hepatic tissue iron index proposed by Bassett et al was evaluated in 35 patients with homozygous genetic haemochromatosis, 67 patients with alcoholic liver disease, and 18 patients with other forms of chronic liver disease with and without cirrhosis. In patients with cirrhosis hepatic tissue iron concentration reliably differentiated alcoholic liver disease from genetic haemochromatosis. Although mean iron concentration was greater in patients with prefibrotic haemochromatosis than in those with prefibrotic alcoholic liver disease, some overlap occurred and complete differentiation of the two conditions was not possible. This overlap was particularly evident in some young patients with haemochromatosis in whom the tissue iron concentration grade fell in the range commonly seen in alcoholic haemosiderosis. Inability to differentiate early genetic haemochromatosis from alcoholic liver disease complicated by haemosiderosis was also a problem with standard Perls's staining. When the hepatic tissue iron index was calculated (hepatic tissue iron concentration/patient's age in years), clear differentiation of genetic haemochromatosis from both alcoholic liver disease and other forms of chronic liver disease was obtained in both cirrhotic and precirrhotic patients. This study confirms that the hepatic tissue iron index is a useful means of differentiating patients with genetic haemochromatosis from those with alcoholic liver disease. We suggest that biochemical estimation of tissue iron concentration and calculation of the tissue iron index in all patients in whom genetic haemochromatosis is a possible diagnosis will reduce the likelihood of misdiagnosing this as alcoholic liver disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864543      PMCID: PMC1378810          DOI: 10.1136/gut.32.2.207

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  8 in total

1.  Prevalence of hemochromatosis among 11,065 presumably healthy blood donors.

Authors:  C Q Edwards; L M Griffen; D Goldgar; C Drummond; M H Skolnick; J P Kushner
Journal:  N Engl J Med       Date:  1988-05-26       Impact factor: 91.245

2.  Idiopathic hemochromatosis and iron overload in alcoholic liver disease: differentiation by HLA phenotype.

Authors:  M Simon; M Bourel; B Genetet; R Fauchet; G Edan; P Brissot
Journal:  Gastroenterology       Date:  1977-10       Impact factor: 22.682

3.  Normal human iron storage and its relation to ethanol consumption.

Authors:  L W Powell
Journal:  Australas Ann Med       Date:  1966-05

4.  Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis.

Authors:  C Niederau; R Fischer; A Sonnenberg; W Stremmel; H J Trampisch; G Strohmeyer
Journal:  N Engl J Med       Date:  1985-11-14       Impact factor: 91.245

5.  Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods.

Authors:  P Brissot; M Bourel; D Herry; J P Verger; M Messner; C Beaumont; F Regnouard; B Ferrand; M Simon
Journal:  Gastroenterology       Date:  1981-03       Impact factor: 22.682

6.  Serum ferritin as a possible marker of the hemochromatosis allele.

Authors:  C Beaumont; M Simon; R Fauchet; J P Hespel; P Brissot; B Genetet; M Bourel
Journal:  N Engl J Med       Date:  1979-07-26       Impact factor: 91.245

7.  Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis.

Authors:  M L Bassett; J W Halliday; L W Powell
Journal:  Hepatology       Date:  1986 Jan-Feb       Impact factor: 17.425

8.  Survival and causes of death in hemochromatosis. Observations in 163 patients.

Authors:  G Strohmeyer; C Niederau; W Stremmel
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

  8 in total
  8 in total

Review 1.  Hepatic iron deposition in human disease and animal models.

Authors:  J W Halliday; J Searle
Journal:  Biometals       Date:  1996-04       Impact factor: 2.949

2.  Hepatic iron overload in thalassemic patients: proposal and validation of an MRI method of assessment.

Authors:  M G Bonetti; A Castriota-Scanderbeg; G M Criconia; P Mazza; M Sacco; B Amurri; C Masi
Journal:  Pediatr Radiol       Date:  1996-09

Review 3.  Assessing the Non-tumorous Liver: Implications for Patient Management and Surgical Therapy.

Authors:  Pallavi Pandey; Ankur Pandey; Mary Dillhoff; Carl Schmidt; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2017-09-18       Impact factor: 3.452

4.  Non-invasive methods for liver fibrosis prediction in hemochromatosis: One step beyond.

Authors:  Agustin Castiella; Eva Zapata; José M Alústiza
Journal:  World J Hepatol       Date:  2010-07-27

5.  Iron overload in urban Africans in the 1990s.

Authors:  I T Gangaidzo; V M Moyo; T Saungweme; H Khumalo; R M Charakupa; Z A Gomo; M Loyevsky; R Stearman; T La Vaute; E G Enquist; T A Rouault; V R Gordeuk
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

6.  Evidence for altered hepatic matrix degradation in genetic haemochromatosis.

Authors:  D K George; G A Ramm; L W Powell; L M Fletcher; N I Walker; L L Cowley; D H Crawford
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

7.  Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Bruce R Bacon; Paul C Adams; Kris V Kowdley; Lawrie W Powell; Anthony S Tavill
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

8.  Hepatic iron in African Americans who underwent liver biopsy.

Authors:  James C Barton; Luigi F Bertoli; Thomas J Alford; J Clayborn Barton; Corwin Q Edwards
Journal:  Am J Med Sci       Date:  2015-01       Impact factor: 2.378

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.